Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets Journal Article
| Authors: | Lopez-Bujanda, Z. A.; Hadavi, S. H.; Ruiz De Porras, V.; Martínez-Balibrea; Dallos, M. C. |
| Article Title: | Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets |
| Title Series: | International Review of Cell and Molecular Biology |
| Abstract: | Prostate cancer (PCa) stands as a significant global health concern, ranking among the leading causes of cancer deaths in men. While there are several treatment modalities for localized PCa, metastatic castration-resistant PCa (mCRPC) remains incurable. Despite therapeutic advancements showing promise in mCRPC, their impact on overall survival has been limited. This chapter explores the process by which tumors form, reviews our current understanding of PCa progression to mCRPC, and addresses the challenges of boosting anti-tumor immune responses in these tumors. It specifically discusses how chemotactic signaling affects the tumor microenvironment and its role in immune evasion and cancer progression. The chapter further examines the rationale of directly or indirectly targeting these pathways as adjuvant therapies for mCRPC, highlighting recent pre-clinical and clinical studies currently underway. The discussion emphasizes the potential of targeting specific chemokines and chemokine receptors as combination therapies with mainstream treatments for PCa and mCRPC to maximize long-term survival for this deadly disease. © 2024 |
| Keywords: | signal transduction; cancer chemotherapy; cancer survival; treatment response; cancer growth; nonhuman; drug targeting; cancer adjuvant therapy; cancer radiotherapy; antineoplastic agent; animal; metabolism; animals; interleukin 8; pathology; cancer hormone therapy; prostate cancer; prostatic neoplasms; clinical study; immune response; chemotaxis; prostate tumor; cell migration; drug therapy; gamma interferon inducible protein 10; therapy; chemotactic factor; antineoplastic hormone agonists and antagonists; chemokine receptor ccr2; immunocompetent cell; monocyte chemotactic protein 1; castration resistant prostate cancer; cxcl9 chemokine; stromal cell derived factor 1; tumor microenvironment; molecularly targeted therapy; chemokine receptor cxcr4; molecular targeted therapy; chemokine receptor cxcr3; chemokine receptor ccr5; rantes; tumor escape; immunosuppressive; cxcl11 chemokine; chemokine receptor cxcr2; immune checkpoint inhibitor; long term survival; combination drug therapy; preclinical study; chemokine receptors; humans; human; male; anti-tumor immune response; prostatic neoplasms, castration-resistant; metastatic castration resistant prostate cancer; immunogenic; tumor microenvironment (tme); prostate cancer (pca); antigenic escape; checkpoint inhibitor therapy; chemo-sensitivity; chemo-sensitizers; chemotactic modulation; chemotactic signaling pathways; chemotaxis affecting agent; lymphotactin |
| Journal Title: | International Review of Cell and Molecular Biology |
| Volume: | 388 |
| ISSN: | 1937-6448 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-01-01 |
| Start Page: | 162 |
| End Page: | 205 |
| Language: | English |
| DOI: | 10.1016/bs.ircmb.2024.03.008 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter 6 in "Chemokine Receptors in Health and Disease" (ISBN: 978-0-443-22172-9) -- Source: Scopus |
